| Ceramide synthesis and metabolism as a target for cancer therapy CP Reynolds, BJ Maurer, RN Kolesnick Cancer letters 206 (2), 169-180, 2004 | 450 | 2004 |
| Retinoid therapy of high-risk neuroblastoma CP Reynolds, KK Matthay, JG Villablanca, BJ Maurer Cancer letters 197 (1-2), 185-192, 2003 | 391 | 2003 |
| Increase of ceramide and induction of mixed apoptosis/necrosis by N-(4-hydroxyphenyl)-retinamide in neuroblastoma cell lines BJ Maurer, LS Metelitsa, RC Seeger, MC Cabot, CP Reynolds Journal of the National Cancer Institute 91 (13), 1138-1146, 1999 | 326 | 1999 |
| Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl) retinamide and modulators of ceramide metabolism BJ Maurer, L Melton, C Billups, MC Cabot, CP Reynolds Journal of the National Cancer Institute 92 (23), 1897-1909, 2000 | 256 | 2000 |
| Evaluating response to antineoplastic drug combinations in tissue culture models C Patrick Reynolds, BJ Maurer Chemosensitivity: Volume 1 In Vitro Assays, 173-183, 2005 | 168 | 2005 |
| N-(4-hydroxyphenyl) retinamide elevates ceramide in neuroblastoma cell lines by coordinate activation of serine palmitoyltransferase and ceramide synthase H Wang, BJ Maurer, CP Reynolds, MC Cabot Cancer research 61 (13), 5102-5105, 2001 | 163 | 2001 |
| Pharmacologic inhibition of STAT5 in acute myeloid leukemia B Wingelhofer, B Maurer, EC Heyes, AA Cumaraswamy, A Berger-Becvar, ... Leukemia 32 (5), 1135-1146, 2018 | 141 | 2018 |
| N-(4-Hydroxyphenyl)retinamide increases dihydroceramide and synergizes with dimethylsphingosine to enhance cancer cell killing H Wang, BJ Maurer, YY Liu, E Wang, JC Allegood, S Kelly, H Symolon, ... Molecular cancer therapeutics 7 (9), 2967-2976, 2008 | 119 | 2008 |
| Retinoic‐acid‐resistant neuroblastoma cell lines show altered MYC regulation and high sensitivity to fenretinide CP Reynolds, Y Wang, LJ Melton, PA Einhorn, DJ Slamon, BJ Maurer Medical and Pediatric Oncology: The Official Journal of SIOP—International …, 2000 | 113 | 2000 |
| N-(4-hydroxyphenyl) retinamide increases ceramide and is cytotoxic to acute lymphoblastic leukemia cell lines, but not to non-malignant lymphocytes PH O'Donnell, WX Guo, CP Reynolds, BJ Maurer Leukemia 16 (5), 902-910, 2002 | 103 | 2002 |
| Fenretinide cytotoxicity for Ewing’s sarcoma and primitive neuroectodermal tumor cell lines is decreased by hypoxia and synergistically enhanced by ceramide modulators S Batra, CP Reynolds, BJ Maurer Cancer research 64 (15), 5415-5424, 2004 | 102 | 2004 |
| Novel submicroscopic extrachromosomal elements containing amplified genes in human cells BJ Maurer, E Lai, BA Hamkalo, L Hood, G Attardi Nature 327 (6121), 434-437, 1987 | 95 | 1987 |
| Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL A Schrader, G Crispatzu, S Oberbeck, P Mayer, S Pützer, J von Jan, ... Nature communications 9 (1), 697, 2018 | 89 | 2018 |
| STAT5BN642H is a driver mutation for T cell neoplasia HTT Pham, B Maurer, M Prchal-Murphy, R Grausenburger, ... The Journal of clinical investigation 128 (1), 387-401, 2018 | 84 | 2018 |
| Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: a report from the New Approaches to … BJ Maurer, MH Kang, JG Villablanca, J Janeba, S Groshen, KK Matthay, ... Pediatric blood & cancer 60 (11), 1801-1808, 2013 | 80 | 2013 |
| NOX4-driven ROS formation mediates PTP inactivation and cell transformation in FLT3ITD-positive AML cells AK Jayavelu, JP Müller, R Bauer, SA Böhmer, J Lässig, S Cerny-Reiterer, ... Leukemia 30 (2), 473-483, 2016 | 77 | 2016 |
| Improved Oral Delivery of N-(4-Hydroxyphenyl)Retinamide with a Novel LYM-X-SORB Organized Lipid Complex BJ Maurer, O Kalous, DW Yesair, X Wu, J Janeba, V Maldonado, ... Clinical cancer research 13 (10), 3079-3086, 2007 | 70 | 2007 |
| CDK6 is an essential direct target of NUP98 fusion proteins in acute myeloid leukemia J Schmoellerl, IAM Barbosa, T Eder, T Brandstoetter, L Schmidt, B Maurer, ... Blood, The Journal of the American Society of Hematology 136 (4), 387-400, 2020 | 60 | 2020 |
| Treatment of hyperproliferative disorders BJ Maurer, M Cabot, CP Reynolds US Patent 6,352,844, 2002 | 58 | 2002 |
| STAT5A and STAT5B—twins with different personalities in hematopoiesis and leukemia B Maurer, S Kollmann, J Pickem, A Hoelbl-Kovacic, V Sexl Cancers 11 (11), 1726, 2019 | 56 | 2019 |
